Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Katy, bar the door! HIV entry inhibitors.

Martinez LJ.

Res Initiat Treat Action. 2000 Jun;6(2):6-12. No abstract available.

PMID:
11707878
2.

Inhibition of virus entry: an antiviral mechanism of emerging prominence.

Koszalka GW, Meanwell NA.

Curr Opin Investig Drugs. 2006 Feb;7(2):106-8. No abstract available.

PMID:
16499279
3.

HIV entry inhibitors: progress in development and application.

Lai WH, Huang L, Chen CH.

Yao Xue Xue Bao. 2010 Feb;45(2):131-40. Review.

PMID:
21348414
4.

Upcoming drugs that inhibit viral entry will be a new frontier for antiretroviral therapy.

Murphy MJ.

HIV Clin. 2002 Fall;14(4):1-3. No abstract available.

PMID:
12434756
5.

HIV entry and fusion inhibitors.

Chantry D.

Expert Opin Emerg Drugs. 2004 May;9(1):1-7. Review.

PMID:
15155132
6.

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.

J Med Virol. 2004 Sep;74(1):21-8.

PMID:
15258964
7.

Novel therapies based on mechanisms of HIV-1 cell entry.

Kilby JM, Eron JJ.

N Engl J Med. 2003 May 29;348(22):2228-38. Review. No abstract available.

PMID:
12773651
8.

[Enfuvirtide. Two injections per day for HIV].

Taéron C.

Rev Infirm. 2004 Oct;(104):35-6. French. No abstract available.

PMID:
15581312
9.

Fusion inhibitors: T-20 and T-1249.

[No authors listed]

TreatmentUpdate. 2001 Spring;12(12):2-3. No abstract available.

PMID:
11570088
10.

Preventing viral entry. Fusion inhibitors.

Marks N.

Posit Living. 1999 Mar;8(2):13. No abstract available.

PMID:
12491997
11.

Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Matthews T, Salgo M, Greenberg M, Chung J, DeMasi R, Bolognesi D.

Nat Rev Drug Discov. 2004 Mar;3(3):215-25. Review.

PMID:
15031735
12.

Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.

[No authors listed]

TreatmentUpdate. 2006 Aug-Sep;18(4):4. No abstract available.

PMID:
17205653
13.

HIV entry inhibitors: mechanisms of action and resistance pathways.

Briz V, Poveda E, Soriano V.

J Antimicrob Chemother. 2006 Apr;57(4):619-27. Epub 2006 Feb 7. Review.

PMID:
16464888
14.

Drug profile: enfuvirtide (Fuzeon, ENF, T-20).

Pham PA.

Hopkins HIV Rep. 2003 May;15(3):1-2. No abstract available.

PMID:
12809104
15.

Entry inhibitors: a race to the finish line.

[No authors listed]

Proj Inf Perspect. 2006 Jan;(40):7-12. No abstract available.

PMID:
16718905
16.

Advances in HIV treatment include HIV envelope tropism and inhibition.

Besch CL.

HIV Clin. 2008 Winter;20(1):1-3. No abstract available.

PMID:
18574885
17.

Discontinuation of the clinical development of fusion inhibitor T-1249.

Martin-Carbonero L.

AIDS Rev. 2004 Jan-Mar;6(1):61. No abstract available.

PMID:
15168742
18.

[Originality of entry inhibitors].

Izopet J.

Med Mal Infect. 2009 Oct;39(10 Suppl 1):H1-4. Review. French. No abstract available.

PMID:
19837343
19.

HIV entry inhibitors: a new generation of antiretroviral drugs.

Krambovitis E, Porichis F, Spandidos DA.

Acta Pharmacol Sin. 2005 Oct;26(10):1165-73. Review.

20.

Chemokine receptors as new molecular targets for antiviral therapy.

Santoro F, Vassena L, Lusso P.

New Microbiol. 2004 Apr;27(2 Suppl 1):17-29. Review.

PMID:
15646061

Supplemental Content

Support Center